SCHEMBL4896085

SCHEMBL4896085

CC(C)(C)c1cc(C(C)(C)C)c(O)c(S(=O)(=O)Nc2ccc(C#N)cc2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 2/20 0.50
MCL1 Q07820 2/20 0.49
BRD4 O60885 1/20 0.47
ALDH1A1 P00352 4/20 0.45
IDH1 O75874 1/20 0.45
ACLY P53396 2/20 0.45
KDM1A O60341 1/20 0.45
UQCRB P14927 1/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
KDM4E B2RXH2 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
HPGD P15428 1/20 0.42
HIF1A Q16665 1/20 0.42
CYP19A1 P11511 1/20 0.41
MAPT P10636 2/20 0.41
LMNA P02545 1/20 0.41
BRD1 O95696 1/20 0.39
BRPF1 P55201 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4885016 0.88 BRD4 (0.53) SLC22A12MCL1BRD4ALDH1A1IDH1
SCHEMBL4893186 0.86 SLC22A12 (0.49) SLC22A12MCL1BRD4ALDH1A1IDH1
SCHEMBL4890245 0.83 MCL1 (0.54) SLC22A12MCL1BRD4IDH1ACLY
SCHEMBL4898138 0.83 SLC22A12 (0.57) SLC22A12MCL1ACLYHPGD
SCHEMBL4890178 0.82 MCL1 (0.47) SLC22A12MCL1BRD4IDH1ACLY
SCHEMBL14023341 0.72 SLC22A12 (0.55) SLC22A12ACLY
SCHEMBL4893835 0.71 SLC22A12 (0.57) SLC22A12MCL1ALDH1A1ACLYMEN1
SCHEMBL8971657 0.71 ALDH1A1 (0.44) ALDH1A1CA1CA2MEN1KMT2A
SCHEMBL4893777 0.71 SLC22A12 (0.56) SLC22A12ACLYMEN1KMT2A
SCHEMBL4894222 0.70 ALDH1A1 (0.48) MCL1ALDH1A1IDH1UQCRBCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255240-A1 Sulfonamide Derivatives NOVO NORDISK A/S (DK) 2008-10-16 US claimed
EP-1756025-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2007-02-28 EP claimed
WO-2005105712-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2005-11-10 WO claimed
US-20080255240-A1 Sulfonamide Derivatives NOVO NORDISK A/S (DK) 2008-10-16 US disclosed
EP-1756025-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2007-02-28 EP disclosed
WO-2005105712-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255240-A1 Sulfonamide Derivatives FABP4, SQOR, CS SLC22A12 1558/4885MCL1 4068/4885BRD4 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.